ESLA (Estrella Immunopharma) Other Current Receivables: $0.18 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ESLA Estrella Immunopharma Inc ESLA
12 GF Score
Price $0.71
! 1 Warning Sign
View Full Analysis

What is Estrella Immunopharma Other Current Receivables?

Estrella Immunopharma ESLA -1.11% 12 Other Current Receivables is $0.18 Mil as of Jun. 2026. GuruFocus rates ESLA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Estrella Immunopharma's Other Current Receivables for the quarter that ended in Jun. 2026 was $0.18 Mil.

Estrella Immunopharma's quarterly Other Current Receivables declined from Dec. 2025 ($0.29 Mil) to Mar. 2026 ($0.23 Mil) but then stayed the same from Mar. 2026 ($0.23 Mil) to Jun. 2026 ($0.18 Mil).

Estrella Immunopharma's annual Other Current Receivables increased from Jun. 2023 ($0.00 Mil) to Jun. 2024 ($0.29 Mil) and increased from Jun. 2024 ($0.29 Mil) to Dec. 2025 ($0.29 Mil).

Estrella Immunopharma Other Current Receivables Related Terms

Estrella Immunopharma Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Estrella Immunopharma's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Estrella Immunopharma Other Current Receivables Chart

Estrella Immunopharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Dec25
Other Current Receivables
0.00 0.00 0.00 0.29 0.29

Estrella Immunopharma Quarterly Data
Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.40 0.29 0.23 0.18
ESLA
12GF Score
Estrella Immunopharma Inc ESLA
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Estrella Immunopharma Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of $0.18 Mil mean?
Estrella Immunopharma (ESLA) has a Other Current Receivables of $0.18 Mil as of Jun. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Estrella Immunopharma and its competitors.
Is Estrella Immunopharma's Other Current Receivables too high?
Estrella Immunopharma's current Other Current Receivables is $0.18 Mil. Overall, Estrella Immunopharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Estrella Immunopharma's Other Current Receivables compare to LITS and NNVC?
Estrella Immunopharma's Other Current Receivables of $0.18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Estrella Immunopharma and its competitors. Estrella Immunopharma's current Other Current Receivables is $0.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Estrella Immunopharma stock overvalued right now?
Estrella Immunopharma (ESLA) has a current Other Current Receivables of $0.18 Mil. The current Other Current Receivables is $0.18 Mil. Estrella Immunopharma's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Estrella Immunopharma (ESLA), the current Other Current Receivables is $0.18 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Estrella Immunopharma Business Description

Address 5858 Horton Street, Suite 370, Emeryville, CA, USA, 94608
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.
12GF Score

Get the complete analysis for ESLA

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.71
Price